Tango Therapeutics - About the company
Tango Therapeutics is a public company based in Cambridge (United States), founded in 2017 by and . It operates as a Developer of drugs for the treatment of cancer. Tango Therapeutics has raised $165M in funding from Casdin Capital and Boxer Capital. The company has 3081 active competitors, including 1076 funded and 722 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and BeiGene.
Company Details
Tango Therapeutics is a biotech company developing novel drugs for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. The company is discovering novel targets using synthetic lethality, where the cancer-causing alteration in a tumour suppressor gene creates a vulnerability that leads to the destruction of the tumour cell.
- Website
- Email ID
- @tangotx.com
- Phone Number
- +1
Key Metrics
Founded Year
2017
Location
Cambridge, United States
Stage
Public
Total Funding
in 4 rounds
Latest Funding Round
Investors
Ranked
110th among 3081 active competitors
Annual Revenue
as on Dec 31, 2022
Employee Count
as on Dec 31, 2023
Similar Companies
Exit Details
Public
Legal entities associated with Tango Therapeutics
Tango Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
May 20, 2020 | $24.9M (as on Dec 31, 2022) | 241 | 565 | |
- | 677 | 147 |
Get your free copy of Tango Therapeutics's company profile
Tango Therapeutics's funding and investors
Tango Therapeutics has raised a total funding of $165M over 4 rounds. Its first funding round was on Mar 30, 2017.
Tango Therapeutics has 8 institutional investors including Casdin Capital, Boxer Capital and Third Rock Ventures.
Here is the list of recent funding rounds of Tango Therapeutics:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Aug 10, 2023 | $80M | Post IPO | 8528286 | 1806105 | - |
Aug 17, 2020 | $50M | Series B | 9913065 | 5984790 | Casdin Capital, Boxer Capital, and |
Apr 09, 2020 | $60M | Series B | 2728653 | 3355837 |
Access funding benchmarks and valuations. Sign up today!View details of Tango Therapeutics's funding rounds and investors
Tango Therapeutics's founders and board of directors
The founders of Tango Therapeutics are and . is the CEO of Tango Therapeutics. has founded 1 more company - Foundation Medicine. has founded 1 more company - Sample6.
View details of Tango Therapeutics's Founder profiles and Board Members
Tango Therapeutics's employee count trend
Tango Therapeutics has 140 employees as of Dec 23. The total employee count is 27.3% more than what it was in Dec 22. Here is Tango Therapeutics's employee count trend over the years:
Uncover Tango Therapeutics's growth story! Sign up today!Tango Therapeutics's Competitors and alternates
Top competitors of Tango Therapeutics include Jazz Pharmaceuticals, Moderna and BeiGene. Here is the list of Top 10 competitors of Tango Therapeutics, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of therapeutics for cancer and neurological disorders | $265M | Lehman Brothers, Golden Gate CapitalÌý&²¹³¾±è;Ìý | 86/100 |
2nd |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | Viking Global Investors, Sylvain ZimmerÌý&²¹³¾±è;Ìý | 85/100 |
3rd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | T. Rowe Price, MerckÌý&²¹³¾±è;Ìý | 84/100 |
4th |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | Tamburi Investment Partners, NaxicapÌý&²¹³¾±è;Ìý | 83/100 |
5th | Recursion 2013, United States, Public | R&D based company focused on manufacturing of drugs for multiple therapeutic areas | $452M | Obvious Ventures, Kilmahew VenturesÌý&²¹³¾±è;Ìý | 81/100 |
6th | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | Ridgeback Capital Management, CHL Medical PartnersÌý&²¹³¾±è;Ìý | 78/100 |
7th |  Revolution Medicines 2014, Redwood City (United States), Public | Developer of therapies for treating cancer | $181M | Third Rock Ventures, Colt VenturesÌý&²¹³¾±è;Ìý | 78/100 |
8th | Blueprint Medicines 2008, Cambridge (United States), Public | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | Third Rock Ventures, Ridgeback Capital ManagementÌý&²¹³¾±è;Ìý | 77/100 |
9th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | Delos Capital Partners, Avoro Capital AdvisorsÌý&²¹³¾±è;Ìý | 77/100 |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | Lightchain Capital, The Kraft GroupÌý&²¹³¾±è;Ìý | 76/100 |
110th |  2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | Third Rock Ventures, RocheÌý&²¹³¾±è;Ìý | 60/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Tango Therapeutics's competitors? Click to see the top ones
Tango Therapeutics's Investments and acquisitions
Tango Therapeutics has made no investments or acquisitions yet.
Reports related to Tango Therapeutics
Here is the latest report on Tango Therapeutics's sector:
View
News related to Tango Therapeutics
Media has covered Tango Therapeutics for a total of 15 events in the last 1 year, 12 of them have been about company updates.
•
•
MarketBeat•Apr 22, 2025•Tango Therapeutics
•
GlobeNewswire•Mar 26, 2025•Tango Therapeutics
•
GlobeNewswire•Feb 27, 2025•Tango Therapeutics
•
Benzinga•Jan 30, 2025•Tango Therapeutics
•
Business Wire•Nov 06, 2024•Tango Therapeutics
•
Business Wire•Nov 06, 2024•Tango Therapeutics
•
Fierce Biotech•Nov 06, 2024•Tango Therapeutics
•
Business Wire•Aug 07, 2024•Tango Therapeutics
•
Business Wire•May 23, 2024•Tango Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about Tango Therapeutics
When was Tango Therapeutics founded?
Tango Therapeutics was founded in 2017.Where is Tango Therapeutics located?
Tango Therapeutics is located in Cambridge, United States.When was the latest funding round of Tango Therapeutics?
Tango Therapeutics's latest funding round was on Aug 10, 2023.What is the annual revenue of Tango Therapeutics?
Annual revenue of Tango Therapeutics is $24.9M as on Dec 31, 2022.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- mca-systems.co.uk - Unfunded company
- Vayudh - Delhi based, 2016 founded, Series A company
- Lending Solutions - India based, 2015 founded, Unfunded company
- TECNA Group - Acquaviva delle Fonti based, 1997 founded, Unfunded company
- Marzi - Bengaluru based, 2024 founded, Unfunded company
- InnoMethods - Dublin based, 2009 founded, Unfunded company
